1 The EIC Accelerator Project
EIC Accelerator Program: An Overview
The European Innovation Council (EIC) Accelerator program is a key component of the European Union’s strategy to support innovation and entrepreneurship within the DeepTech and startup ecosystems. This program is designed specifically to assist small and medium-sized enterprises (SMEs) and startups in bringing their groundbreaking ideas to market. The EIC Accelerator provides both grant funding and equity investment, facilitating the scaling of high-potential innovations.
Funding Structure
The EIC Accelerator offers a two-pronged funding structure comprising grants and equity investments:
Purpose and Impact
The primary goal of the EIC Accelerator is to foster innovation in the European market, particularly in sectors characterized by high technological complexity and potential disruption, such as DeepTech. By providing funding and support, the program helps companies scale their operations, attract further investments, and enhance their chances of success in competitive markets.
Through its support, the EIC Accelerator plays a pivotal role in reducing the risks associated with innovation. It helps startups navigate the often challenging landscape of funding, enabling them to secure additional financing from private investors by demonstrating the viability of their projects and the backing of a reputable European initiative.
Case Study: INVIVO BIONICS AS and the PRESSURO Project
Company Overview: INVIVO BIONICS AS, based in Norway, specializes in developing innovative medical technologies. The company focuses on addressing critical healthcare challenges through cutting-edge solutions.
Project Acronym: PRESSURO
Project Description: The PRESSURO project aims to create a revolutionary Pressure Sensor System specifically designed for urodynamics. This technology addresses global challenges related to urinary storage and voiding problems, which affect a significant portion of the population, particularly the elderly and those with chronic health conditions.
Funding Type: Under the EIC Accelerator program, INVIVO BIONICS AS received grant funding first, which will support the research and development phases of the PRESSURO project.
Project Submission Date: The company submitted its Step 2 proposal on March 23, 2022, and subsequently advanced to the Step 3 interview, ultimately securing funding.
Technology Background
The PRESSURO project is anchored in advanced sensor technology that seeks to improve the diagnostic capabilities in urodynamic assessments. Urodynamics involves measuring the pressure in the bladder and the flow of urine, which is critical for diagnosing conditions such as urinary incontinence, overactive bladder syndrome, and bladder outlet obstruction.
Technical Aspects:
- Innovative Sensor Design: The PRESSURO system leverages cutting-edge pressure sensor technology that offers enhanced accuracy and reliability in measurements. This is crucial for obtaining precise data during urodynamic tests.
- User-Centric Approach: The design of the PRESSURO system emphasizes ease of use and patient comfort. This includes minimizing invasiveness and improving the overall experience for both patients and healthcare providers.
- Data Integration: The system is designed to integrate seamlessly with existing medical technologies, allowing for real-time data analysis and monitoring. This can significantly expedite diagnosis and treatment planning, leading to better patient outcomes.
- Global Health Implications: The technology addresses a pressing global health issue, potentially improving the quality of life for millions suffering from urinary disorders.
Conclusion
The EIC Accelerator program serves as a vital lifeline for innovative startups like INVIVO BIONICS AS. By providing substantial grant funding and equity investment, the program not only supports the development of groundbreaking technologies such as the PRESSURO project but also strengthens the overall European startup ecosystem. With its focus on addressing critical health issues, the PRESSURO project exemplifies the transformative potential of DeepTech innovations backed by robust funding and strategic support.
2 The Funding Rounds
Financing Raised by INVIVO BIONICS AS (Norway) Since EIC Accelerator Funding
Overview
INVIVO BIONICS AS, based in Oslo, Norway, develops innovative microsensor systems for monitoring and managing urinary dysfunction. The company was awarded EIC Accelerator funding after submitting its Step 2 proposal on March 23, 2022. Below is a summary of available information on its financing activity and investment landscape since that date.
Funding Rounds & Amounts
As of the current date, there is no publicly available evidence indicating that INVIVO BIONICS AS has announced or closed additional significant funding rounds beyond its EIC Accelerator grant since March 2022. The company’s website and recent media releases focus primarily on product development—particularly around their PRESSURO® bladder pressure monitoring system—and do not reference new equity investments or venture capital rounds.
- There are no disclosed Series A/B/C or later-stage venture capital funding rounds.
- No information has surfaced regarding seed extensions, bridge financing, or convertible note rounds in this period.
Timing and Details of Funding Rounds
- EIC Accelerator Grant: Awarded after the March 23, 2022 cutoff; exact amount not specified but typically ranges up to €2.5 million in non-dilutive grant support for winning companies under this program.
- No subsequent private investment round (e.g., from VCs or angel investors) has been formally announced post-EIC award as per currently accessible sources up to April 30, 2025.
Investor Information
- There is no public record of new institutional investors joining INVIVO BIONICS AS following their EIC win.
- The company’s leadership includes individuals with investor backgrounds (notably John Solberg as an investor/advisor), but these relationships predate the EIC grant.
- No major VC firms have been listed as backers since early 2022.
Company Valuations
No valuation data for INVIVO BIONICS AS has been made public following their receipt of the EIC Accelerator award. This lack of disclosure suggests they have not undertaken a priced equity round that would require setting a formal post-money valuation.
Exit Events: IPOs & Acquisitions
There have been no announcements related to exit events such as:
- Initial Public Offerings (IPOs)
- Acquisitions
- Strategic buyouts involving INVIVO BIONICS AS since its EIC funding success.
The company's communications remain focused on advancing clinical development and technology partnerships rather than preparing for liquidity events.
Summary Table: Post-EIC Accelerator Financial Activity
| Date | Event/Type | Amount | Investors | Notes |
|---|---|---|---|---|
| Mar–Apr 2022 | EIC Accelerator Grant | Not disclosed | European Commission | Non-dilutive innovation grant |
| Apr 2025 | No additional fundraising reported |
</em>Typical maximum €2.5M for winners; specific figure unconfirmed for INVIVO BIONICS AS.
Conclusion
Since receiving the prestigious EU-backed EIC Accelerator grant in spring/summer 2022, INVIVO BIONICS AS has concentrated efforts on product innovation and building strategic clinical partnerships rather than raising further dilutive capital or pursuing exit opportunities. As of April 30th, 2025:
- No new financing rounds are publicly documented.
- Investor composition appears unchanged post-EIC win.
- There are no known company valuation updates nor any reported exit transactions.
Sources
About Us - InVivo Bionics InVivo Partners with Thoughtworks to Empower Urologists with Data ... Funding Rounds Explained: Series A, B, C and Seed - Coresignal3 The Press Releases
InVivo Bionics: Post-EIC Accelerator Funding Developments (2022–Present)Since securing EIC Accelerator funding in March 2022, InVivo Bionics AS (Norway) has advanced its mission to revolutionize urologic care through its flagship PRESSURO® microsensor system, designed for real-time bladder pressure monitoring. Below are key developments:
Core Technology & Clinical Impact
- PRESSURO® Innovation: A microsensor implant that provides continuous bladder pressure data, enabling personalized treatment plans for urologic conditions.
- Regulatory Progress: Actively pursuing FDA approval alongside existing CE marking efforts in Europe to expand market access.
Strategic Partnerships & Collaborations
- Thoughtworks Alliance: Partnered with Thoughtworks in May 2023 to enhance data integration and analytics capabilities for PRESSURO®, improving clinical decision-making tools for urologists.
- Global Clinical Network: Collaborates with leading urologists and medical institutions to refine sensor performance and validate clinical utility.
Team Expertise & Leadership
The Oslo-based team includes specialists in biomedical engineering, regulatory strategy, and clinical medicine:- Dr. Ingelin Clausen (CEO): PhD in physical electronics, focusing on implantable sensors since 2008.
- Daniel Aragao (CTO): Software engineering expert overseeing secure data architecture development.
- Medical advisors ensure alignment with clinical standards during product iterations.
Market Strategy & Future Directions
Focused on penetrating regions with high demand for advanced urologic solutions, including markets affected by age-related bladder dysfunction or spinal cord injuries. The company emphasizes scalable manufacturing and clinician training programs to accelerate adoption.Sources Used in This Article
-InVivo Partners with Thoughtworks [Press Release] | InVivo Bionics Team | SME Business Review Profile4 The Technology Advancements
InVivo Bionics AS: Current Capabilities and Advancements
InVivo Bionics AS, based in Oslo, Norway, is a medical device company known for developing innovative pressure sensor systems, particularly for bladder function monitoring. Founded in 2018, the company has been actively involved in advancing its technology to provide better insights for urologists.
Current Capabilities
InVivo Bionics offers a microsensor system called PRESSURO, designed to measure and monitor bladder functions continuously. This technology is based on more than a decade of research and development at SINTEF. The system is unique because it allows for long-term continuous measurements based on the natural filling of the bladder, providing new insights into bladder function. This capability can help clinicians avoid failed surgeries and trial-and-error approaches with medications, especially beneficial for the approximately 900 million people worldwide suffering from urinary dysfunction.Advancements Since EIC Accelerator Funding
Following the receipt of EIC Accelerator funding on March 23, 2022, InVivo Bionics has continued to enhance its technology. While specific details about new features directly related to this funding are not available, the company has been focused on clinical trials and improving its pressure sensor system. In 2023, InVivo Bionics conducted clinical trials focusing on safety, feasibility, and performance, aligning with MDR conformity efforts.Market Demonstration and Clinical Trials
InVivo Bionics has been involved in various clinical stages, including prototype testing in humans since 2014. By 2023, they had progressed to conducting clinical trials, which indicates significant progress in demonstrating their technology to the market. However, specific details about customer engagements or pilots are not readily available.Patents and Scientific Publications
There is no recent information available on new patents filed or scientific studies published by InVivo Bionics specifically since receiving the EIC Accelerator funding. The company has, however, collaborated with Thoughtworks to enhance data capabilities for urologists, indicating ongoing development efforts.In summary, InVivo Bionics continues to refine its bladder pressure monitoring system, with a focus on clinical trials and improving its technology. While specific advancements directly tied to the EIC funding are not detailed, the company remains committed to transforming urological care.
Sources:
- Home — InVivo Bionics
- InVivo Bionics
- InVivo Partners with Thoughtworks to Empower Urologists with Data ...
- InVivo Bionics AS - Norway Health Tech
- 25 impressive medical device startups to watch in 2025 - Qualio
5 The Partnerships and Customers
InVivo Bionics AS: Partnerships and Market Positioning
InVivo Bionics AS, a Norwegian company, has been enhancing its presence in the medical technology sector since winning the EIC Accelerator funding in March 2022. The company is renowned for its innovative bladder pressure monitoring system, PRESSURO®, designed to revolutionize urodynamic assessments.
Partnerships and Customers
- Thoughtworks Partnership: InVivo Bionics has partnered with Thoughtworks to empower urologists with data-driven insights, improving patient treatments. This collaboration is focused on leveraging technology to enhance clinical decision-making.
- Strategic Alliances: The company has established strong alliances with healthcare providers and academic institutions worldwide. These partnerships facilitate real-world data collection and feedback, enabling InVivo Bionics to refine its products based on clinical needs.
- Clinical Collaborations: InVivo Bionics collaborates with a network of clinical experts, contributing to the development of advanced biomedical solutions.
New Partners and Customers
While specific details on new partners or customers are not currently highlighted in available sources, the ongoing partnership with Thoughtworks suggests a focus on integrating technology to improve clinical outcomes. The company's strategic alliances with healthcare providers and academic institutions continue to be a key part of its market strategy.
Nature and Purpose of New Relationships
The partnerships established by InVivo Bionics aim to enhance its technological capabilities and market presence. By collaborating with technology companies like Thoughtworks and engaging with clinical experts, InVivo Bionics positions itself to advance its sensor technology and expand its reach in the global healthcare market.
Market Positioning and Technology Advancements
These partnerships will help InVivo Bionics AS in several ways: - Technology Advancements: Collaborations facilitate access to cutting-edge technology and expertise, allowing for the refinement and expansion of InVivo Bionics' product line.
- Scaling: Strategic partnerships aid in navigating complex regulatory landscapes and accessing new markets, which is crucial for the widespread adoption of its innovative products.
- Market Positioning: By enhancing its technological offerings and expanding its network, InVivo Bionics strengthens its market presence as a leader in advanced medical devices.
Conclusion
InVivo Bionics AS continues to solidify its position in the medical technology sector through strategic partnerships and technological advancements. The company's focus on improving patient outcomes and expanding its market reach positions it for continued growth and innovation in the healthcare industry.
Sources
- InVivo Partners with Thoughtworks to Empower Urologists with Data
- How a Medical Device Company Doubled Their Speed to Market
- Ingelin Clausen, Dr. Scient, CEO & Founder, InVivo Bionics
- Thoughtworks Partners With InVivo Bionics to Help Urologists in Providing Patient Treatments
- About Us - InVivo Bionics
- InVivo Bionics AS - Norway Health Tech
6 The Hiring and Company Growth
InVivo Bionics: Team Growth and Development
InVivo Bionics, a Norwegian medical device company, has been recognized for its innovative approaches in the health sector, particularly since receiving the EIC Accelerator funding in March 2022. Here is an overview of the company's recent developments and growth:
Current Team Size and Headcount
The specific headcount of InVivo Bionics is not publicly disclosed, but it is described as a small, hand-picked team of skilled professionals. The team includes a mix of scientists, business developers, and serial entrepreneurs working alongside clinical experts from around the world.Hiring and Recruitment
InVivo Bionics is actively hiring, with recent job postings for positions like systems developers. They are looking for individuals passionate about innovation, quality, and problem-solving to join their team.Growth and Scaling
Since receiving the EIC Accelerator funding, InVivo Bionics has continued to develop its cutting-edge IoT technology, focusing on pressure sensor systems that can revolutionize the field of urology. This technology aims to provide medical experts with better insights and more accurate diagnoses, potentially expanding into other medical fields in the future.Key Positions and Recent Hires
While specific recent hires are not detailed, the company emphasizes the importance of quality engineering and innovation. Key positions include roles in engineering, software development, and clinical advisory capacities.Impact of New Team Members
New team members at InVivo Bionics are crucial for scaling and growth, as they contribute to the development of advanced technologies and innovative medical solutions. These additions help the company maintain its position as a leader in medical innovation, particularly in Norway and Europe.Major Changes in Management
There is no public information on significant changes in the founding team or management structure since the EIC funding. The core leadership includes Ingelin Clausen as CEO & Founder, Trond Johansen as CCO, Daniel Aragao as CTO, and Sayed Rahimi as CFO & COO.Sources
7 The Media Features and Publications
Media Features and Public Presence of InVivo Bionics AS InVivo Bionics AS, a Norwegian medtech company specializing in bladder pressure monitoring solutions, has garnered attention for its PRESSURO® microsensor system. The Oslo-based firm collaborates with Thoughtworks to enhance urological diagnostics, leveraging continuous pressure monitoring technology developed through over a decade of R&D at SINTEF[^1^]. While specific EIC Accelerator-related media coverage isn’t explicitly documented in available sources, the company’s innovations have been highlighted in industry reports and partnerships.Publications Mentioning InVivo Bionics AS
MPO Magazine featured the company’s collaboration with Thoughtworks to improve urological treatments using its MEMS-based sensor[^2^]. Norway Health Tech’s member profile details InVivo Bionics’ mission to address urinary dysfunction affecting 900 million people globally[^3^], while Qualio’s case study emphasizes how the startup doubled its speed to market with quality-focused strategies[^4^].
Podcasts and Interviews
No direct interviews or podcasts featuring InVivo Bionics’ team were identified in the search results. However, Citeline’s In Vivo Podcast series focuses broadly on biopharma trends without specific mention of the company[^5^].
Conference Participation and Events
While no explicit conference appearances are listed, Norway Health Tech membership suggests involvement in regional healthcare innovation networks. The 4th In Vivo Cell Engineering & Gene Editing Summit (unrelated to InVivo Bionics) highlights industry interest in in vivo therapies but does not list this company among participants^6^.
Sources
- [Thoughtworks, InVivo Bionics Partner to Improve Urological Treatment
- InVivo Bionics AS - Norway Health Tech
- How a medical device company doubled their speed to market
- In Vivo Podcasts From Citeline - SoundCloud
- In Vivo Cell Engineering & Gene Editing Summit | Home (Note: URL corrected from typo)*
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.